Peficitinib

Peficitinib
Clinical data
Trade names	Smyraf
Other names	ASP015K; JNJ-54781532
ATC code	L04AF06 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
CAS Number	944118-01-8;
PubChem CID	57928403;
UNII	HPH1166CKX;
KEGG	D10721;
Chemical and physical data
Formula	C18H22N4O2
Molar mass	326.400 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(=O)c1cnc2[nH]ccc2c1NC1[C@H]2CC3C[C@@H]1CC(O)(C3)C2;
	InChI InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11 ,1 ; Key:DREIJXJRTLTGJC-JQCLMNFQSA-N ;

Peficitinib (brand name Smyraf) is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors (JAK inhibitors).^[1]^[2]

Peficitinib was approved for use in Japan in 2019.^[3]

References

^ Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, et al. (April 2017). "Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate". Arthritis & Rheumatology. 69 (4): 709–719. doi:10.1002/art.39955. PMID 27748083.709-719&rft.date=2017-04&rft_id=info:doi/10.1002/art.39955&rft_id=info:pmid/27748083&rft.aulast=Kivitz&rft.aufirst=AJ&rft.au=Gutierrez-Ureña, SR&rft.au=Poiley, J&rft.au=Genovese, MC&rft.au=Kristy, R&rft.au=Shay, K&rft.au=Wang, X&rft.au=Garg, JP&rft.au=Zubrzycka-Sienkiewicz, A&rft_id=https://doi.org/10.1002%2Fart.39955&rfr_id=info:sid/en.wikipedia.org:Peficitinib" class="Z3988">
^ Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, et al. (May 2017). "Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis". Arthritis & Rheumatology. 69 (5): 932–942. doi:10.1002/art.40054. PMID 28118538.932-942&rft.date=2017-05&rft_id=info:doi/10.1002/art.40054&rft_id=info:pmid/28118538&rft.aulast=Genovese&rft.aufirst=MC&rft.au=Greenwald, M&rft.au=Codding, C&rft.au=Zubrzycka-Sienkiewicz, A&rft.au=Kivitz, AJ&rft.au=Wang, A&rft.au=Shay, K&rft.au=Wang, X&rft.au=Garg, JP&rft.au=Cardiel, MH&rft_id=https://doi.org/10.1002%2Fart.40054&rfr_id=info:sid/en.wikipedia.org:Peficitinib" class="Z3988">
^ Markham A, Keam SJ (June 2019). "Peficitinib: First Global Approval". Drugs. 79 (8): 887–891. doi:10.1007/s40265-019-01131-y. PMID 31093950. S2CID 155093525.887-891&rft.date=2019-06&rft_id=https://api.semanticscholar.org/CorpusID:155093525#id-name=S2CID&rft_id=info:pmid/31093950&rft_id=info:doi/10.1007/s40265-019-01131-y&rft.aulast=Markham&rft.aufirst=A&rft.au=Keam, SJ&rfr_id=info:sid/en.wikipedia.org:Peficitinib" class="Z3988">

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, et al. (April 2017). "Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate". Arthritis & Rheumatology. 69 (4): 709–719. doi:10.1002/art.39955. PMID 27748083.709-719&rft.date=2017-04&rft_id=info:doi/10.1002/art.39955&rft_id=info:pmid/27748083&rft.aulast=Kivitz&rft.aufirst=AJ&rft.au=Gutierrez-Ureña, SR&rft.au=Poiley, J&rft.au=Genovese, MC&rft.au=Kristy, R&rft.au=Shay, K&rft.au=Wang, X&rft.au=Garg, JP&rft.au=Zubrzycka-Sienkiewicz, A&rft_id=https://doi.org/10.1002%2Fart.39955&rfr_id=info:sid/en.wikipedia.org:Peficitinib" class="Z3988">

[2] Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, et al. (May 2017). "Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis". Arthritis & Rheumatology. 69 (5): 932–942. doi:10.1002/art.40054. PMID 28118538.932-942&rft.date=2017-05&rft_id=info:doi/10.1002/art.40054&rft_id=info:pmid/28118538&rft.aulast=Genovese&rft.aufirst=MC&rft.au=Greenwald, M&rft.au=Codding, C&rft.au=Zubrzycka-Sienkiewicz, A&rft.au=Kivitz, AJ&rft.au=Wang, A&rft.au=Shay, K&rft.au=Wang, X&rft.au=Garg, JP&rft.au=Cardiel, MH&rft_id=https://doi.org/10.1002%2Fart.40054&rfr_id=info:sid/en.wikipedia.org:Peficitinib" class="Z3988">

[3] Markham A, Keam SJ (June 2019). "Peficitinib: First Global Approval". Drugs. 79 (8): 887–891. doi:10.1007/s40265-019-01131-y. PMID 31093950. S2CID 155093525.887-891&rft.date=2019-06&rft_id=https://api.semanticscholar.org/CorpusID:155093525#id-name=S2CID&rft_id=info:pmid/31093950&rft_id=info:doi/10.1007/s40265-019-01131-y&rft.aulast=Markham&rft.aufirst=A&rft.au=Keam, SJ&rfr_id=info:sid/en.wikipedia.org:Peficitinib" class="Z3988">

[1]

[2]

[3]